Steroid-toxicity Insights Roundup
The STOX® Suite of steroid-toxicity assessments has been used prospectively in more than 80 clinical trials of novel steroid-sparing treatments versus standard of care. Now, one of those assessments - the GTI-MD is being used retrospectively to interrogate large datasets for steroid-toxicity in claims and electronic medical records (EHR) at the population level. Health economics outcomes research (HEOR) is an essential part of enabling researchers to demonstrate the cost-effectiveness of different therapies.
A pioneering analysis in myasthenia gravis, just presented at ISPOR, has demonstrated that the GTI-MD can reliably quantify steroid-toxicity from EHR. This breakthrough promises to revolutionize HEOR research, enabling drug developers and healthcare decision-makers to recognize the true cost of steroids, and apply that knowledge to shift the cost-benefit conversations around treatment decisions.
In Conversation With...Glenn Philips, PhD
Glenn Philips, PhD is the Vice President of Health Economics and Outcomes Research at pharmaceutical company Argenx. Dr Philips trained as a clinical psychologist with a specialization in research design and statistics. His expertise lies in leading research projects, designing and analyzing clinical trials, and representing the unique needs of health outcomes in drug development efforts.
Quantifying the Risk-Benefit Ratio of Steroids in Myasthenia Gravis
Pioneering analysis of electronic health record data finally quantifies the risk-to-benefit ratio of prescribing glucocorticoids.
Steroid-toxicity Drives Increased Organ Damage in Lupus Nephritis
Recent research has shown that for many lupus nephritis patients, the cure may be at least as damaging as the disease in terms of organ damage.
Recommended by LinkedIn
Experience the STOX® Digital Platform
Your free trial of the GTI-MD is waiting for you. Experience it now >
Steritas is working toward a world free of steroid dependency, enabling the measurement and monitoring of steroid-toxicity to optimize treatment of inflammatory diseases and improve the quality of patient care around the world.
Learn more at steritas.com.
Sincerely,
Martha Stone
CEO, Steritas